Sionna Therapeutics, Inc. (SION) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 221.54M USD. 52-week range 4.01 to 54.97 USD. Data as of 2026-10-09.
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a ...